167 related articles for article (PubMed ID: 29807073)
21. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB.
Brummelkamp TR; Nijman SM; Dirac AM; Bernards R
Nature; 2003 Aug; 424(6950):797-801. PubMed ID: 12917690
[TBL] [Abstract][Full Text] [Related]
22. The tumor suppressor CYLD regulates entry into mitosis.
Stegmeier F; Sowa ME; Nalepa G; Gygi SP; Harper JW; Elledge SJ
Proc Natl Acad Sci U S A; 2007 May; 104(21):8869-74. PubMed ID: 17495026
[TBL] [Abstract][Full Text] [Related]
23. Truncation of the catalytic domain of the cylindromatosis tumor suppressor impairs lung maturation.
Trompouki E; Tsagaratou A; Kosmidis SK; Dollé P; Qian J; Kontoyiannis DL; Cardoso WV; Mosialos G
Neoplasia; 2009 May; 11(5):469-76. PubMed ID: 19412431
[TBL] [Abstract][Full Text] [Related]
24. The K48-K63 Branched Ubiquitin Chain Regulates NF-κB Signaling.
Ohtake F; Saeki Y; Ishido S; Kanno J; Tanaka K
Mol Cell; 2016 Oct; 64(2):251-266. PubMed ID: 27746020
[TBL] [Abstract][Full Text] [Related]
25. CYLD Alterations in the Tumorigenesis and Progression of Human Papillomavirus-Associated Head and Neck Cancers.
Cui Z; Kang H; Grandis JR; Johnson DE
Mol Cancer Res; 2021 Jan; 19(1):14-24. PubMed ID: 32883697
[TBL] [Abstract][Full Text] [Related]
26. Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial.
Cranston A; Stocken DD; Stamp E; Roblin D; Hamlin J; Langtry J; Plummer R; Ashworth A; Burn J; Rajan N
Trials; 2017 Mar; 18(1):111. PubMed ID: 28270164
[TBL] [Abstract][Full Text] [Related]
27. Thymocyte-specific truncation of the deubiquitinating domain of CYLD impairs positive selection in a NF-kappaB essential modulator-dependent manner.
Tsagaratou A; Trompouki E; Grammenoudi S; Kontoyiannis DL; Mosialos G
J Immunol; 2010 Aug; 185(4):2032-43. PubMed ID: 20644164
[TBL] [Abstract][Full Text] [Related]
28. Cylindromatosis Tumor Suppressor Protein (CYLD) Deubiquitinase is Necessary for Proper Ubiquitination and Degradation of the Epidermal Growth Factor Receptor.
Sanchez-Quiles V; Akimov V; Osinalde N; Francavilla C; Puglia M; Barrio-Hernandez I; Kratchmarova I; Olsen JV; Blagoev B
Mol Cell Proteomics; 2017 Aug; 16(8):1433-1446. PubMed ID: 28572092
[TBL] [Abstract][Full Text] [Related]
29. CYLD dysregulation in pathogenesis of sporadic inclusion body myositis.
Yamashita S; Matsuo Y; Tawara N; Hara K; Yamamoto M; Nishikami T; Kawakami K; Zhang X; Zhang Z; Doki T; Ando Y
Sci Rep; 2019 Aug; 9(1):11606. PubMed ID: 31406156
[TBL] [Abstract][Full Text] [Related]
30. miR-130b, an onco-miRNA in bladder cancer, is directly regulated by NF-κB and sustains NF-κB activation by decreasing Cylindromatosis expression.
Cui X; Kong C; Zhu Y; Zeng Y; Zhang Z; Liu X; Zhan B; Piao C; Jiang Z
Oncotarget; 2016 Jul; 7(30):48547-48561. PubMed ID: 27391066
[TBL] [Abstract][Full Text] [Related]
31. CYLD expression in dendritic cells involved in the immunoregulation of pulmonary adenocarcinoma via NF-κB pathway.
Yu Q; Lei Y; Huang Y; Zhang J; Chen Y; Chen K; Lin J; Sun S; Lin X
Artif Cells Nanomed Biotechnol; 2020 Dec; 48(1):137-142. PubMed ID: 31852310
[TBL] [Abstract][Full Text] [Related]
32. CYLD destabilizes NoxO1 protein by promoting ubiquitination and regulates prostate cancer progression.
Haq S; Sarodaya N; Karapurkar JK; Suresh B; Jo JK; Singh V; Bae YS; Kim KS; Ramakrishna S
Cancer Lett; 2022 Jan; 525():146-157. PubMed ID: 34742871
[TBL] [Abstract][Full Text] [Related]
33. CYLD in health and disease.
Marín-Rubio JL; Raote I; Inns J; Dobson-Stone C; Rajan N
Dis Model Mech; 2023 Jun; 16(6):. PubMed ID: 37387450
[TBL] [Abstract][Full Text] [Related]
34. Regulation of early wave of germ cell apoptosis and spermatogenesis by deubiquitinating enzyme CYLD.
Wright A; Reiley WW; Chang M; Jin W; Lee AJ; Zhang M; Sun SC
Dev Cell; 2007 Nov; 13(5):705-716. PubMed ID: 17981138
[TBL] [Abstract][Full Text] [Related]
35. CYLD regulates keratinocyte differentiation and skin cancer progression in humans.
Alameda JP; Fernández-Aceñero MJ; Moreno-Maldonado R; Navarro M; Quintana R; Page A; Ramírez A; Bravo A; Casanova ML
Cell Death Dis; 2011 Sep; 2(9):e208. PubMed ID: 21900959
[TBL] [Abstract][Full Text] [Related]
36. A novel large deletion of the CYLD gene causes CYLD cutaneous syndrome in a Chinese family.
Zhu R; Xu J; Shen J; Li W; Tan F; Li C; Wei Z; Liu Y; Bai Y
Mol Genet Genomic Med; 2020 Oct; 8(10):e1441. PubMed ID: 32783365
[TBL] [Abstract][Full Text] [Related]
37. CYLD deficiency enhances metabolic reprogramming and tumor progression in nasopharyngeal carcinoma via PFKFB3.
Wang L; Lin Y; Zhou X; Chen Y; Li X; Luo W; Zhou Y; Cai L
Cancer Lett; 2022 Apr; 532():215586. PubMed ID: 35131382
[TBL] [Abstract][Full Text] [Related]
38. Expression of CYLD, NF-kappaB and NF-kappaB-related factors in salivary gland tumors.
Fukuda M; Fukuda F; Horiuchi Y; Oku Y; Suzuki S; Kusama K; Sakashita H
In Vivo; 2006; 20(4):467-72. PubMed ID: 16900776
[TBL] [Abstract][Full Text] [Related]
39. Immune dysregulation in SHARPIN-deficient mice is dependent on CYLD-mediated cell death.
Ang RL; Chan M; Legarda D; Sundberg JP; Sun SC; Gillespie VL; Chun N; Heeger PS; Xiong H; Lira SA; Ting AT
Proc Natl Acad Sci U S A; 2021 Dec; 118(50):. PubMed ID: 34887354
[TBL] [Abstract][Full Text] [Related]
40. CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin.
Wickström SA; Masoumi KC; Khochbin S; Fässler R; Massoumi R
EMBO J; 2010 Jan; 29(1):131-44. PubMed ID: 19893491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
